



US009408852B2

(12) **United States Patent**
Gidner et al.

(10) **Patent No.:** **US 9,408,852 B2**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **METHOD OF LOWERING SERUM URIC ACID LEVELS WITH (S)-TOFISOPAM**

(75) Inventors: **Judi Gidner**, Yardley, PA (US); **Karen Raudibaugh**, North Wales, PA (US); **Brian Speicher**, Hackensack, NJ (US)

(73) Assignee: **PHARMOS CORPORATION**, West Palm Beach, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 849 days.

(21) Appl. No.: **13/558,491**

(22) Filed: **Jul. 26, 2012**

(65) **Prior Publication Data**

US 2013/0045966 A1 Feb. 21, 2013

Related U.S. Application Data

(60) Provisional application No. 61/512,114, filed on Jul. 27, 2011.

(51) **Int. Cl.**

A61K 31/551 (2006.01)

A61P 9/12 (2006.01)

A61P 13/12 (2006.01)

A61P 19/06 (2006.01)

A61K 45/06 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/551** (2013.01); **A61K 45/06** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

| | | | |
|------------------|---------|-----------------|---------|
| 6,649,607 B2 | 11/2003 | Leventer et al. | |
| 6,864,251 B2 | 3/2005 | Kucharik et al. | |
| 7,078,398 B2 | 7/2006 | Leventer et al. | |
| 2004/0138209 A1 | 7/2004 | Kucharik et al. | |
| 2004/0162284 A1 | 8/2004 | Harris et al. | |
| 2004/0229866 A1 | 11/2004 | Harris et al. | |
| 2005/0288277 A1* | 12/2005 | Kucharik et al. | 514/221 |
| 2007/0032479 A1 | 2/2007 | Leventer et al. | |

OTHER PUBLICATIONS

Kelley, A Specific Enzyme Defect in Gout Associated with Overproduction of Uric Acid, *Biochemistry*, 1967, 57, pp. 1735-1739.*
Aug. 2010, Pharms Presentation, S. Colin Neill, pp. 1-21.
Form 10-Q from Pharms 3rd quarter, filed Oct. 27, 2010, pp. 1-31 and Exhibit 31.1, 31.2, 32.1 and 32.2.
Feb. 17, 2011 Pharms Press Release, pp. 1-4.

* cited by examiner

Primary Examiner — San-Ming Hui

Assistant Examiner — Andrew Lee

(74) *Attorney, Agent, or Firm* — Drinker Biddle & Reath LLP

(57) **ABSTRACT**

Enantiomerically-pure (S)-tofisopam is administered to lower serum uric acid levels in a mammal.

19 Claims, No Drawings